Immunogenicity and safety of a Trivalent Influenza HA vaccine in Indonesian infants and children.
Vaccine
; 36(16): 2126-2132, 2018 04 12.
Article
em En
| MEDLINE
| ID: mdl-29551225
ABSTRACT
INTRODUCTION:
High rate of influenza infection in children made influenza vaccination strongly recommended for all person aged >6â¯months in Indonesia. Bio Farma Trivalent Influenza HA (Flubio®) vaccine has been used in adolescents and adults, resulted in increased seroconversion, seroprotection rates and geometric mean titer (GMT). However, no data is available regarding its efficacy and safety in children. This study aimed to assess the immunogenicity and safety of Flubio® vaccine in infants and children. MATERIALS ANDMETHODS:
This was a phase II, open-labeled, clinical trial conducted on healthy children aged 6â¯month-11â¯years, vaccinated with 1 or 2 doses of Influenza HA vaccine, with a 28-day interval. Flubio® vaccine composed of A/California/7/2009 (H1N1) pandemic 09, A/Texas/50/2012 (H3N2), and B/Massachusetts/2/2012 strain. This study was held at East Jakarta, Indonesia from May until July 2014. A Total of 405 subjects were included and divided into three groups A(6-35â¯months), B(3-8â¯years), and C(9-11â¯years). Antibody titer was measured at visit V1 (Day 0), V2 (28â¯days/+7days after the first dose) and V3 (28â¯days/+7days after second dose). The seroprotection and seroconversion rates were assessed. Safety was assessed up to 28â¯days following each dose.RESULTS:
A total of 404 subjects completed the study. After vaccination, all subjects achieved seroprotection and increased seroconversion rates, with post-vaccination antibody titer of ≥140 HI for all strains. The GMT also increased significantly. Within 30â¯min after vaccination, 14.6% and 2% had local and systemic reactions; meanwhile, between 30â¯min to 72â¯h after vaccination, 35.1% and 13.6% subjects had local and systemic reactions, respectively. Most reactions were mild. No serious adverse event (SAE) was reported related to vaccine.CONCLUSION:
Flubio® (Influenza HA Trivalent) vaccine is immunogenic and safe for children aged 6â¯months-11â¯years. TRIAL REGISTRATION The trial is registered at the US National Institutes of Health (ClinicalTrials.gov) #NCT02093260.Palavras-chave
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Vacinas contra Influenza
/
Vacinação
/
Glicoproteínas de Hemaglutininação de Vírus da Influenza
/
Influenza Humana
/
Imunogenicidade da Vacina
Tipo de estudo:
Clinical_trials
Limite:
Child
/
Child, preschool
/
Female
/
Humans
/
Infant
/
Male
/
Newborn
País/Região como assunto:
Asia
Idioma:
En
Revista:
Vaccine
Ano de publicação:
2018
Tipo de documento:
Article
País de afiliação:
Indonésia